HSPA1A and cerebral malaria: These reported dual inhibitory activities on Hsp90 and Hsp70 chaperones, coupled with the ability to cross the BBB, and protect neurons (Youn et al., 2022), suggest that epigallocatechin-3-gallate may be a promising candidate in the management of cerebral malaria.